Although exciting, the drug industry can be a dog eat dog world. If you have invented a drug yourself, you will be more than aware of the patent and monopoly processes that come with it. However, when a patent expires you are left right back where you started. 

This can be hard to swallow, and some companies often find themselves going to extreme lengths to avoid parting with their profits. STAT writes, Allergen hit the headlines last week by doing exactly this. They surprised the pharma world by announcing that they had sold patent rights on a lucrative eye drug to a Native American tribe all to avoid facing particular legal challenges by generics.

Believe it or not, there are some tricks in the book that drug makers often turn to in such situations in order to squeeze a few more pennies out of their ageing inventions.

Read the full article here.